T1	Participants 104 122	metabolic syndrome
T2	Participants 163 195	patients with metabolic syndrome
T3	Participants 449 481	subjects with metabolic syndrome
T4	Participants 487 540	treated with allopurinol (n = 28) or placebo (n = 22)
T5	Participants 1578 1610	patients with metabolic syndrome
